Meghan Scanlon - Jul 27, 2021 Form 4 Insider Report for BOSTON SCIENTIFIC CORP (BSX)

Role
SVP,Pres,Urology Pelvic Health
Signature
/s/ Vance R. Brown, Attorney-in-fact
Stock symbol
BSX
Transactions as of
Jul 27, 2021
Transactions value $
-$299,160
Form type
4
Date filed
7/27/2021, 08:28 PM
Previous filing
Jul 6, 2021
Next filing
Aug 4, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BSX Common Stock Options Exercise $324K +13.9K +72.35% $23.41 33K Jul 27, 2021 Direct F1, F2
transaction BSX Common Stock Sale -$623K -13.9K -41.98% $45.01 19.1K Jul 27, 2021 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BSX Stock Option (Right to Buy) Options Exercise $0 -13.9K -100% $0.00* 0 Jul 27, 2021 Common Stock 13.9K $23.41 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan.
F2 Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.
F3 Represents the weighted average sale price. These shares were sold in multiple transactions at $45.00 and $45.02. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F4 Grant to the reporting person of an option to purchase 13,850 shares of common stock vesting in four equal annual installments beginning on July 1, 2017, the first anniversaryof the date of grant.